Notwithstanding encouraging clinical results, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant difficulty from PBMs. These insurers are frequently https://alvintkng928833.jaiblogs.com/69116758/the-drug-faces-is-dealing-with-managed-care-organization-challenges-a-review-of-reimbursement-fights